Skip to content

Study · Animal study (in vivo) · mouse · 2010

9 results

Bioactivity and pharmacokinetics of two human serum albumin-thymosin alpha1-fusion proteins, rHSA-Talpha1 and rHSA-L-Talpha1, expressed in recombinant Pichia pastoris.

Chen JH, Zhang XG, Jiang YT, Yan LY, Tang L, Yin YW, Cheng DS, Chen J, Wang M

Cancer immunology, immunotherapy : CII16 May 2010Cited by 15 (Europe PMC)

PMID20473755 (opens in a new tab)PMCIDPMC11030058 (opens in a new tab)DOI10.1007/s00262-010-0862-9 (opens in a new tab)PepBankPUB-20473755
Source linkPubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In hydrocortisone-induced immunosuppressed mice, seven days of subcutaneous Talpha1 (pooled with two fusion proteins) significantly improved the net body weight increment.

    In plain wordsIn mice with drug-induced immune suppression, seven days of thymosin alpha‑1 injections improved body weight gain.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseNet body weight increment
    Study

    mousen: not reported in source

    Hydrocortisone-induced immunosuppression mice
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 7 daysAs given in this study (mouse).

    Source sentences

    Summary
    In hydrocortisone-induced immunosuppression mice (in vivo experiments), after subcutaneous injections with two fusion proteins and Talpha1 for seven consecutive days, the net increment of body weight, the spleen index and the thymus index were significantly improved.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In hydrocortisone-induced immunosuppressed mice, seven days of subcutaneous Talpha1 (pooled with two fusion proteins) significantly improved the spleen index.

    In plain wordsIn mice with drug-induced immune suppression, seven days of thymosin alpha‑1 injections improved the spleen index.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseSpleen index
    Study

    mousen: not reported in source

    Hydrocortisone-induced immunosuppression mice
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated · subcutaneous · 7 daysAs given in this study (mouse).

    Source sentences

    Summary
    In hydrocortisone-induced immunosuppression mice (in vivo experiments), after subcutaneous injections with two fusion proteins and Talpha1 for seven consecutive days, the net increment of body weight, the spleen index and the thymus index were significantly improved.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In hydrocortisone-induced immunosuppressed mice, seven days of subcutaneous Talpha1 (pooled with two fusion proteins) significantly improved the thymus index.

    In plain wordsIn mice with drug-induced immune suppression, seven days of thymosin alpha‑1 injections improved the thymus index.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseThymus index
    Study

    mousen: not reported in source

    Hydrocortisone-induced immunosuppression mice
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated · subcutaneous · 7 daysAs given in this study (mouse).

    Source sentences

    Summary
    In hydrocortisone-induced immunosuppression mice (in vivo experiments), after subcutaneous injections with two fusion proteins and Talpha1 for seven consecutive days, the net increment of body weight, the spleen index and the thymus index were significantly improved.
  4. 04LabIn vitro (cells)Activity measurement

    In murine spleen lymphocytes in vitro, Talpha1 treatment (like the two fusion proteins) was linked to a higher degree of T cell maturation than normal spleen cells.

    In plain wordsIn cells from mouse spleens, thymosin alpha‑1 treatment was linked to more mature T cells than in normal spleen cells.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseT cell maturation of spleen lymphocytes in vitro
    Study

    mousen: not reported in source

    Murine spleen lymphocytes
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In contrast to the reactivity of normal spleen cells to Con A, the data of in vitro murine spleen lymphocytes proliferation experiment suggested that spleen cells achieved a higher degree of T cell maturation after rHSA-L-Talpha1, rHSA-Talpha1 and Talpha1 treatments, respectively.
  5. 05LabIn vitro (cells)Activity measurement

    In thymocyte sub-populations in vitro, Talpha1 (like the two fusion proteins) antagonized dexamethasone-induced apoptosis.

    In plain wordsIn cells, thymosin alpha‑1 worked against cell death of thymus immune cells caused by dexamethasone.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseDexamethasone-induced thymocyte apoptosis
    Study

    mousen: not reported in source

    Thymocyte sub-populations
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Moreover, rHSA-L-Talpha1, rHSA-Talpha1 and Talpha1 can also antagonize dexamethasone-induced apoptosis of thymocyte sub-populations.

Studies that did not test the peptide alone4

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 06AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Mechanism

    In immunosuppressed mice, plasma SOD level increased after treatment with the fusion proteins and Talpha1 (arm-level attribution is not explicit).

    In plain wordsIn mice with drug-induced immune suppression, a blood antioxidant enzyme rose after treatment that included thymosin alpha‑1.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreasePlasma SOD level
    Study

    mousen: not reported in source

    Hydrocortisone-induced immunosuppression mice
    Outcome group
    Oxidative stress · Immune and inflammation

    Source sentences

    Summary
    In hydrocortisone-induced immunosuppression mice (in vivo experiments), after subcutaneous injections with two fusion proteins and Talpha1 for seven consecutive days, the net increment of body weight, the spleen index and the thymus index were significantly improved. Simultaneously, the increase in…

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 07AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Mechanism

    In immunosuppressed mice, plasma MDA level decreased after treatment with the fusion proteins and Talpha1 (arm-level attribution is not explicit).

    In plain wordsIn mice with drug-induced immune suppression, a blood marker of oxidative damage fell after treatment that included thymosin alpha‑1.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreasePlasma MDA level
    Study

    mousen: not reported in source

    Hydrocortisone-induced immunosuppression mice
    Outcome group
    Oxidative stress · Immune and inflammation

    Source sentences

    Summary
    In hydrocortisone-induced immunosuppression mice (in vivo experiments), after subcutaneous injections with two fusion proteins and Talpha1 for seven consecutive days, the net increment of body weight, the spleen index and the thymus index were significantly improved. Simultaneously, the increase in…

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 08AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Pharmacokinetics

    In rats, the albumin-Talpha1 fusion proteins (not Talpha1 itself) showed an improved pharmacokinetic profile with a prolonged half-life.

    In plain wordsIn rats, the two albumin-fused versions of thymosin alpha‑1 stayed in the body longer.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseHalf-life of the fusion proteins
    Study

    ratn: not reported in source

    Rats
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    The pharmacokinetic data of rHSA-L-Talpha1 and rHSA-Talpha1 administered in rats showed an improved pharmacokinetic profile with a conspicuous prolonged half life.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  4. 09LabNot a test of Thymosin alpha-1 aloneOther designOther

    Three chromatography steps gave fusion proteins (albumin-Talpha1) with purity above 97%.

    In plain wordsIn lab production, the albumin-fused thymosin alpha‑1 proteins reached a purity above 97%.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicablePurity of fusion proteins after chromatography
    Study

    n: not reported in source

    Pichia pastoris expression
    Outcome group
    Synthesis and manufacturing · Pharmacology

    Source sentences

    Summary
    Through the process of ion interaction chromatography (Q-Sepharose F.F), hydrophobic interaction chromatography (Phenyl Sepharose HP) and affinity chromatography (Blue Sepharose F.F), the purity of fusion proteins was greater than 97%.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.